CFTR Modulation Slows Pancreatic Cancer Cell Growth in Preclinical Models

Yunxia O'Malley, Henry Keen, Ian M Thornell et al.

Summary: This laboratory study examined whether restoring CFTR function — via adenoviral transfection or elexacaftor/tezacaftor/ivacaftor (ETI) — affects growth, migration, and gene expression in pancreatic ductal adenocarcinoma (PDAC) cell lines and primary pig pancreatic duct epithelial cells. The investigators found that CFTR-deficient cells showed increased proliferation and migration, and that ETI treatment shifted cell cycle kinetics toward slower replication and suppressed pro-growth transcriptional pathways, including Wnt signaling and key cell cycle regulators, without inducing apoptosis. Public datasets confirmed reduced CFTR expression in human pancreatic cancer tissue relative to normal pancreas.

Why it matters: People with cystic fibrosis carry a substantially elevated risk of gastrointestinal cancers, including pancreatic cancer, compared with the general population — a concern that grows more pressing as CFTR modulators extend life expectancy and as more patients reach ages at which cancer risk accumulates. If CFTR restoration has genuine anti-proliferative effects in pancreatic ductal epithelium, this would carry both mechanistic and clinical implications: it could partially explain cancer risk differences across CFTR genotypes, and it raises the hypothesis that ETI use might eventually prove protective against PDAC in people with CF. That hypothesis deserves rigorous evaluation, though it cannot be confirmed by the present data.

Expert perspective: This is scientifically interesting preclinical work, but it sits firmly in the "promising but preliminary" category and should be read with disciplined expectations. The experimental systems are highly artificial: PANC-1 and CFPAC-1 are established cancer cell lines with extensively remodeled genomes and signaling contexts that diverge substantially from normal or even premalignant pancreatic duct epithelium in a living CF patient. Cell lines are useful for mechanistic hypothesis generation but are notoriously poor predictors of in vivo biology, let alone clinical outcomes.

Restoring CFTR via adenoviral transfection in cancer cell lines produces an acute, supraphysiological expression environment categorically different from the chronic, partial correction achieved by ETI in F508del patients in vivo. The transcriptomic findings — downregulation of cyclins, CDKs, MCM complexes, and Wnt pathway activators in ETI-treated cells — are associative; whether these changes reflect a primary CFTR-mediated effect or secondary responses to altered ion transport, pH, or metabolic state is not established. Notably, ETI appears to slow rather than kill cells — a cytostatic rather than cytotoxic phenotype — and whether this translates into meaningful cancer risk reduction over a lifetime of exposure cannot be addressed by short-term assays. The pig primary duct epithelial cell experiments with wild-type, F508del, and null CFTR genotypes add biological credibility and represent a more physiologically relevant model, which is a methodological strength.

The clinical question that ultimately matters — whether ETI use in people with CF reduces pancreatic cancer incidence or delays its onset — will require long-term registry-based or epidemiological study. CF patient registries, including the US CF Foundation Patient Registry and the European CF Society Patient Registry, are potentially well positioned to begin tracking cancer outcomes longitudinally with adequate granularity, provided ascertainment and linkage to cancer registries are prioritized. The authors are careful not to overclaim, and the work appropriately frames its implications as a starting point for further investigation in organoid models, animal models, and ultimately clinical cohorts — not as a basis for any change in current clinical practice or cancer surveillance recommendations.

Relevance: Cystic Fibrosis

Source: https://pubmed.ncbi.nlm.nih.gov/42731950/

---